"We Remain Optimistic on FDA Approving AXS-005 in Coming Weeks" - Mizuho Securities Reiterates Axsome Therapeutics (AXSM) at Buy with $51 Price Target
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $51.00 price target on Axsome Therapeutics (NASDAQ: AXSM)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
